EDITORIAL

CONFERENCE REPORTS:
XVII International HIV Resistance Workshop (IHDRW), 6-10 June 2008, Sitges

• Introduction
• Integrase inhibitor resistance and cross-resistance: weighing viral fitness and the option to benefit from second-generation compounds
• Understanding etravirine susceptibility: new weighted genotype score and phenotypic cut-offs
• Pipeline antiretrovirals: IDX899, CHX157 and beviramat
• Lack of virological impact of treatment intensification in suppressed patients supports latent viral reservoir as source of residual viraemia
• Detecting viral tropism: impact of a more sensitive Trofile (ES) assay
• NNRTI resistance in infants prophylaxed with single-dose nevirapine varies by the timing of infection
• Low frequency K103N mutations are associated with poor virological response to NNRTI based therapy

CONFERENCE REPORTS:
14th Annual BHIVA Conference, 23–25 April 2008, Belfast

• Introduction
• Bone problems raised in several UK studies
• Late diagnosis in adolescence of vertically acquired HIV infection
• Case study of multi-drug resistant woman receiving newer antiretroviral drugs in pregnancy
• Predictors of treatment failure in Western Cape, South Africa
• Late pregnancy loss in HIV-positive women
• Renal tubular dysfunction with tenofovir-based HAART in four vertically infected adolescents

CONFERENCE REPORTS:
15th Conference on Retroviruses and Opportunistic Infections, Boston, 2-6 February 2008

• Introduction
• The unmet need for contraception services for women receiving ART
• Valacyclovir decreases plasma and genital viral loads in HSV-2/HIV-1 co-infected women
• HPV genotypes in HIV-positive women in Zimbabwe and Uganda

TREATMENT ACCESS

• FDA approval of generic ARVs
• Access to generic efavirenz in South Africa: MSD agrees to grant licenses on reasonable terms
• Reaching ‘3 by 5’…. by 7: new report on universal access
• Oxfam criticises DFID’s new strategy as a “missed opportunity”

ANTIRETROVIRALS

• Boosted atazanavir/r approved in Europe for first-line therapy
• BMS and Merck withdraw 100mg capsule formulation of efavirenz used for paediatric treatment
• Saquinavir (Invirase) interactions with digoxin, garlic capsules, methadone, tipranavir and omeprazole: US label changes
• US label changes for nevirapine paediatric solution
• New US pediatric dosing for lopinavir/r
• New US pediatric dosing for tipranavir/r
• DSMB stops ACTG study with questionable treatment arm due to suboptimal responses

GUIDELINES

• UK (BHIVA) 2008 Treatment Guidelines published online
• Major updates to US guidelines on prevention and treatment of OIs: both adult and paediatric guidelines updated

PREGNANCY & PMTCT

• Low rates of MTCT in UK and Ireland

PAEDIATRICS

• WHO recommends treating all HIV-infected infants aged less than 12 months
• Plasma concentrations and virologic evaluations after stopping NNRTI treatment in PENTA 11

BASIC SCIENCE & VACCINE RESEARCH

• Elite control of a virus that caused AIDS in the transmitting partner
• Presentations from the May 21-23 HIV Vaccine Trials Network (HVTN) Meeting
• Failure of STEP leads TAG to criticise the proposed PAVE100A vaccine trial

OTHER NEWS

• Free osteopathy for people with HIV at the British School of Osteopathy
• AIDS denialists shut out of Senate hearing after winning “whistleblower” award
• MTV internet game challenges assumptions and ignorance about who has HIV

ON THE WEB

• Community publications and resources

FUTURE MEETINGS

PUBLICATIONS AND SERVICES FROM i-BASE

---

Top | htb | Home | Order & subscribe | Contact | Site map | Access